Platelet Transfusions in Critically Ill Patient

Critical Illness Clinical Trial

— RE-CCIP  

Official title:

Platelet Transfusion Efficacy in Critically Ill Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03325140
• Other study ID #: RE-CCIP (29BRC17.0157)
• Status: Recruiting
• Start date: May 30, 2018
• Est. completion date: December 15, 2019

Study information

• Verified date: July 2019
• Source: University Hospital, Brest
• Contact: AUBRON Cécile
• Phone: +33 2 98 34 78 59
• Email: cecile.aubron[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Between 10 and 15% of critically ill patients require platelet transfusion within their intensive care unit (ICU).

Platelets (PLT) are given to prevent bleeding in thrombocytopenic patients or to treat bleeding as part of massive transfusion or in bleeding thrombocytopenic patients.

International and local guidelines (American Association of Blood Banks-AABB) are mainly based on experts' opinion. The efficacy of PLT transfusion in the ICU setting remains poorly studied and unknown and the administration of PLT may be associated with adverse effects including an increased risk of hospital acquired infection. Finally, the short PLT shelve-life may be responsible for inventory issues. Altogether, this makes very important to improve the evidence that support PLT transfusion in ICU patients.

This is a multicentre prospective observational study that aims to first determine PLT transfusion efficacy and to identify the parameters associated with transfusion efficacy and to analyse the compliance with international (and local) guidelines of PLT transfusion in ICU patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 15, 2019
• Est. primary completion date: December 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients admitted to intensive care and receiving at least one platelet transfusion in intensive care unit

Exclusion Criteria:

• Age less than 18

Related Conditions & MeSH terms

• Critical Illness
• Platelet Transfusion

Locations

Country	Name	City	State
France	CHU d'Angers	Angers
France	CHRU de Brest	Brest
France	CH des Pays de Morlaix	Morlaix
France	CHU de Nantes	Nantes
France	CHU de Rennes	Rennes
France	CHU de Tours	Tours
France	Chba Site de Vannes	Vannes

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	platelet transfusion efficacy	corrected count platelet increment	between 18 hours and 28 days after transfusion